Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07597291

Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK)

The goal of this observational study is to evaluate the clinical outcomes and management approaches of cardiogenic shock throughout the years in adult patients admitted to a Cardiology Department. The main questions it aims to answer are:

* How have management strategies and clinical outcomes for cardiogenic shock evolved over time? * How do clinical, laboratory, and advanced hemodynamic monitoring parameters relate to patient survival and overall prognosis in this population?

Researchers will evaluate clinical data collected from 2017 onwards to see if therapeutic advancements and changes in clinical management over the years have led to improved patient survival and quality of care.

Participants will:

* Receive standard, routine medical care for cardiogenic shock as determined by their clinical team (no experimental interventions will be introduced). * Have their clinical, laboratory, and imaging data collected from hospital electronic records during their stay. * Be followed for up to 1 year after hospital admission to evaluate long-term survival and clinical outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Unidade Local de Saúde de Lisboa Ocidental

Carnaxide, Lisbon District, 2790-134, Portugal

Location status: Recruiting

Location contact

Ana Rita Bello, MD

SUB_INVESTIGATOR

Catarina Brízido, MD

CONTACT

[email protected]

+351 21 043 1000

Catarina Brízido, MD

SUB_INVESTIGATOR

Christopher Strong, MD

SUB_INVESTIGATOR

Jorge Ferreira, MD

SUB_INVESTIGATOR

João Presume, MD

CONTACT

[email protected]

+351 21 043 1000

João Presume, MD

PRINCIPAL_INVESTIGATOR

Manuel Sousa Almeida, PhD

SUB_INVESTIGATOR

About this study

The Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK) is hybrid (retrospective and prospective), observational registry designed to evaluate the clinical performance, therapeutic management, and outcomes of patients presenting with cardiogenic shock (CS).

Contemporary CS management has evolved beyond correcting macro-hemodynamic parameters. CS is now recognized as a highly dynamic, systemic syndrome characterized by microvascular hypoperfusion, systemic inflammatory response syndrome (SIRS), endothelial dysfunction, and profound neurohormonal and metabolic derangements. To capture this complexity, the COR-SHOCK registry systematically integrates granular, real-world data reflecting these pathophysiological axes. This includes laboratory evaluation, and advanced invasive hemodynamic profiling via pulmonary artery catheterization (Swan-Ganz).

Registry Procedures and Quality Assurance Plan

To ensure high-quality data collection and compliance with scientific standards, the registry implements the following procedures:

  • Quality Assurance (QA) Plan:

The Steering Committee, led by the Principal Investigator, oversees the registry's operations. Internal data quality audits are conducted semi-annually to review enrollment rates, evaluate protocol adherence, and identify systematic data entry discrepancies.

  • Data Checks:

Data is transcribed from electronic health records into a dedicated electronic database. The entry platform utilizes programmed range validation and consistency rules (e.g., preventing physiological out-of-range values for hemodynamics and laboratory results, and enforcing logical chronological order for clinical events, such as ensuring discharge dates succeed admission dates).

  • Source Data Verification (SDV):

To guarantee data accuracy and completeness, a designated researcher who is not directly involved in the primary data entry performs random source data verification on 10% of all registry entries. This process involves cross-referencing database records with original paper and electronic health records.

  • Data Dictionary:

A comprehensive data dictionary has been established, detailing every variable collected. It defines clinical terminology, laboratory reference ranges, and standardized categorization rules.

  • Standard Operating Procedures (SOPs):

Formal SOPs govern all key registry processes, including:

  • Daily screening and identification of eligible patients in the cardiac intensive care unit (UNICOR).
  • Standardized timing for dynamic data collection.
  • Data security protocols, including patient pseudonymization and password-protected access control.
  • Event reporting protocols for predefined clinical complications.
  • Sample Size Assessment:

The registry aims to include approximately 750 to 800 patients. This target is calculated based on historical admission rates at the center, comprising a retrospective cohort of approximately 500 patients (2017-2025) and a prospective recruitment target of 80 to 100 patients annually over a 2-to-3-year period. This sample size provides sufficient statistical power to characterize temporal trends, evaluate subset populations (e.g., mechanical circulatory support, specific etiologies), and perform robust multivariable risk modeling.

Statistical Analysis Plan (SAP) Descriptive statistics will characterize the study population. Continuous variables will be presented as mean ± standard deviation (SD) or median with interquartile range (IQR), based on normality (assessed via Shapiro-Wilk test). Categorical variables will be expressed as frequencies and percentages.

To evaluate management and outcome trends over the years:

  • Temporal trends in clinical management, therapeutic choices (such as the use of short-duration mechanical circulatory support [VA-ECMO, Impella, IABP] or advanced therapies [LVAD, cardiac transplantation]), and survival will be assessed using linear/logistic regression models across calendar years.
  • Survival curves will be estimated using the Kaplan-Meier method and compared across different clinical phenotypes, therapeutic interventions, and time epochs using the log-rank test.
  • Multivariable Cox proportional hazards regression and logistic regression models will be constructed to identify independent clinical, laboratory and hemodynamic predictors of short-term (ICU and in-hospital) and long-term (1 year) mortality. Model fit and calibration will be evaluated using standard diagnostic metrics (e.g., Harrell's C-index).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-Cardiogenic shock according to the following criteria:

Cardiac disorder resulting in hypotension, defined as at least one of the following:

  • Systolic blood pressure (SBP) <90 mmHg for ≥30 minutes, or
  • Requirement for vasopressors, inotropes, or mechanical circulatory support to maintain SBP ≥90 mmHg

AND

Evidence of tissue hypoperfusion, defined by the presence of at least one of the following:

  • Serum lactate >2 mmol/L
  • Acute kidney injury and/or oliguria
  • Acute hepatic injury
  • Cool or mottled extremities
  • Altered mental status

AND

Clinical presentation judged to be primarily attributable to a cardiac etiology.

Exclusion criteria

  • Age < 18 years.
  • Other primary etiologies of shock at presentation (e.g., hypovolemic, hemorrhagic, septic, obstructive shock due to acute pulmonary embolism, or anaphylactic shock).
  • Refusal to participate in the study (applicable only to the prospective cohort).

Treatment and study plan

Primary outcomes

  1. All-Cause Mortality at 30 days after admission

    Time frame: From date of hospital admission to 30 days after admission

    The proportion of patients presenting with cardiogenic shock who die from any cause during the first 30 days after admission

Secondary outcomes

  1. All-Cause Mortality at 1 Year

    Time frame: At 1 year post-index admission.

    The rate of all-cause mortality evaluated after the index admission. Survival status will be determined via electronic medical records or the national registry ("last seen alive" verification).

  2. Incidence of Major Bleeding up to 30 days after admission

    Time frame: From date of hospital admission to 30 days after admission

    The proportion of patients experiencing major bleeding events up to 30 days after admission. Major bleeding is defined according to the Bleeding Academic Research Consortium (BARC) classification as Type 3 (including 3a, 3b, and 3c) or Type 5 (fatal bleeding).

  3. Incidence of 3-Point Major Adverse Cardiovascular Events (3P-MACE) at 30 days

    Time frame: From date of hospital admission to 30 days after admission

    Thrombotic/ischemic events are defined using the 3-point Major Adverse Cardiovascular Events (3P-MACE) composite, which includes cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke at 30 days after admission.

Other outcomes

  1. Rate of Long-term Ventricular Assist Device (LVAD) Implantation or Heart Transplantation

    Time frame: Up to 1 year post-index admission.

    The percentage of patients transitioning to advanced, long-term therapeutic options, specifically durable Left Ventricular Assist Devices (LVAD, e.g., HeartMate 3) or undergoing heart transplantation as a bridge or destination therapy.

Study contacts

Contact information is provided by the study sponsor or research team.

João Presume, MD

CONTACT

[email protected]

+351 21 043 1000 ext. 3134

Sponsors and collaborators

Lead sponsor

Hospital de Santa Cruz, Portugal

Other

Registry information

Official study title

Cardiovascular Outcomes Registry in Cardiogenic SHOCK

Acronym: COR-SHOCK

Important dates

Study start
2026
Primary completion
2036
Study completion
2036
First posted
May 19, 2026
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.